Your browser doesn't support javascript.
loading
Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors.
Anzalone, Andrew V; Koblan, Luke W; Liu, David R.
Afiliación
  • Anzalone AV; Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Koblan LW; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.
  • Liu DR; Howard Hughes Medical Institute, Harvard University, Cambridge, MA, USA.
Nat Biotechnol ; 38(7): 824-844, 2020 07.
Article en En | MEDLINE | ID: mdl-32572269
ABSTRACT
The development of new CRISPR-Cas genome editing tools continues to drive major advances in the life sciences. Four classes of CRISPR-Cas-derived genome editing agents-nucleases, base editors, transposases/recombinases and prime editors-are currently available for modifying genomes in experimental systems. Some of these agents have also moved rapidly into the clinic. Each tool comes with its own capabilities and limitations, and major efforts have broadened their editing capabilities, expanded their targeting scope and improved editing specificity. We analyze key considerations when choosing genome editing agents and identify opportunities for future improvements and applications in basic research and therapeutics.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Genoma / Sistemas CRISPR-Cas / Edición Génica Límite: Humans Idioma: En Revista: Nat Biotechnol Asunto de la revista: BIOTECNOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Genoma / Sistemas CRISPR-Cas / Edición Génica Límite: Humans Idioma: En Revista: Nat Biotechnol Asunto de la revista: BIOTECNOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos